BofA Securities Maintains Novavax(NVAX.US) With Hold Rating, Maintains Target Price $10
BofA Securities Maintains Novavax(NVAX.US) With Hold Rating, Maintains Target Price $10
BTIG Maintains Novavax(NVAX.US) With Buy Rating, Maintains Target Price $19
Promising Results From Novavax's SHIELD-Utah Study Boost Buy Rating Amid Vaccine Market Dynamics
Novavax's Strategic Positioning and Strong Efficacy Drive Buy Rating
BofA Securities Maintains Novavax(NVAX.US) With Hold Rating, Cuts Target Price to $10
TD Cowen Maintains Novavax(NVAX.US) With Hold Rating, Maintains Target Price $9
Novavax's Regulatory Uncertainty and Market Potential: Hold Rating Maintained
H.C. Wainwright Maintains Novavax(NVAX.US) With Buy Rating, Maintains Target Price $19
BofA Securities Maintains Novavax(NVAX.US) With Hold Rating, Maintains Target Price $12
BTIG Initiates Novavax(NVAX.US) With Buy Rating, Announces Target Price $19
Analysts Offer Insights on Healthcare Companies: Novavax (NVAX) and Ramsay Health Care (OtherRMSYF)
Novavax Initiated With a Buy at BTIG
Novavax: Promising Innovations Amidst Execution and Competitive Challenges – Hold Rating
TD Cowen Initiates Novavax(NVAX.US) With Hold Rating, Announces Target Price $9
BofA Securities Maintains Novavax(NVAX.US) With Hold Rating, Maintains Target Price $12
Bank of America Securities Sticks to Its Hold Rating for Novavax (NVAX)
B.Riley Financial Maintains Novavax(NVAX.US) With Buy Rating, Maintains Target Price $22
Novavax's Strategic Partnerships and Pipeline Developments Drive Buy Rating With Promising Long-term Growth Potential
Novavax Analyst Ratings